ribociclib
novartis
['bcsm', 'kisqali', 'breast']
adding kisqali to endocrine therapy improved invasive disease-free survival in patients with hormone receptor-positive, her2-negative early breast cancer, according to research from #asco23 #bcsm 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.